相关实验视频

Updated: May 5, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

在小鼠中的PRV ΔgE/TK/UL49.5三基因被删除疫苗的免疫性

Chenmeng Ding^1,2,3, Yawei Sun¹, Xianfeng Zhang^1,2

¹College of Veterinary Medicine, Henan Agricultural University, Zhengzhou City, 450046, Henan Province, China.

Virology journal

|February 5, 2025

概括

开发了一种新的伪狂犬病病毒 (PRV) 疫苗菌株,PRV ΔgE/TK/UL49.5. 这种增强的PRV疫苗诱导了强大的免疫力,并保护人免受病毒性PRV挑战.

科学领域:

兽医病毒学兽医病毒学
免疫学免疫学免疫学
疫苗开发疫苗开发

背景情况:

重新出现的伪狂犬病病毒 (PRV) 变种在猪群中造成重大经济损失.
PRV UL49.5蛋白通过通过TAP无活化降低猪白细胞抗原I类 (SLA-I) 表达的调节来逃避宿主免疫.

研究的目的:

构建和评估一个新的PRV三重基因缺失菌株,PRV ΔgE/TK/UL49.5.5.
在小鼠模型中评估其免疫性,保护性有效性和安全性.

主要方法:

使用Cre-LoxP系统建造PRV ΔgE/TK/UL49.5的工程.
增长特征和SLA-I水平的确定.
评估免疫反应 (抗体,细胞因子) 和在免疫小鼠中受到病毒性PRV.挑战的保护.

主要成果:

PRV ΔgE/TK/UL49.5表现出与家长菌株相似的生长,并恢复了正常的SLA-I水平.
免疫接种诱导了高水平的中和抗体和细胞因子 (IFN-γ,IL-4),但没有影响体重增加.
观察到对病毒性PRV挑战的完全保护,病理损伤最小,组织病毒载量最低.

结论:

PRV ΔgE/TK/UL49.5菌株显示出增强的免疫性和保护潜力.
这种新型PRV菌株是未来针对伪狂犬病的疫苗开发的有希望的候选人.

关键词:

免疫性免疫性免疫性伪狂犬病病毒病毒.安全的安全的安全的安全的安全.gE/TK/UL49.5 的删除

更多相关视频

Influenza A Virus Studies in a Mouse Model of Infection

Influenza A Virus Studies in a Mouse Model of Infection

Published on: September 7, 2017

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

相关概念视频

In-vitro Mutagenesis

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.